News | Proton Therapy | October 16, 2020

Mevion Ships the First Compact Accelerator Module to China

Mevion Medical Systems announced that it has shipped the accelerator module for the Mevion S250i Proton Therapy System to Kunshan, China. The 15-ton compact accelerator, the heart of the proton therapy system, is the smallest of its kind and will be the first in China.

Mevion's compact accelerator module is lifted and placed on a truck for the first leg of its journey to China. (Photo: Business Wire)

October 16, 2020 — Mevion Medical Systems announced that it has shipped the accelerator module for the Mevion S250i Proton Therapy System to Kunshan, China. The 15-ton compact accelerator, the heart of the proton therapy system, is the smallest of its kind and will be the first in China.

According to the Global Cancer Observatory, there were 4,285,033 new cancer cases recorded in China in 2018. However, with only 2 proton therapy centers in clinical operation in Mainland China, there is a large cohort of patients without access to this cutting-edge technology.

Proton therapy is a superior form of radiation therapy that can reduce the risk of unnecessary radiation exposure to surrounding healthy tissue and organs at risk. Many types of cancer can benefit from proton therapy, such as lung, breast, and prostate cancer. Pediatric patients with cancers in the brain and central nervous system can significantly benefit from this powerful treatment option.

"This shipment to China, the first of many, is part of Mevion's mission to provide this life-saving technology to as many patients as possible," said Tina Yu, Ph.D., chief executive officer of Mevion Medical Systems. "We are proud to achieve this milestone and open the door to affordable and innovative proton therapy to underserved patients in China."

Single-room proton therapy systems, the dominant global system of choice in recent years, enable more cancer centers in large cities and rural areas the ability to offer this advanced cancer treatment to their patients. With the first shipment from Mevion, China embarks on a new era of single-room proton therapy.

The enormous expenditures and space requirements needed by other single-room or multi-room proton technologies have been a notable impediment to proton therapy adoption worldwide. Mevion changed proton therapy by creating the first and smallest single-room proton therapy system that can be embedded directly into a radiation oncology department and scaled to add additional treatment rooms with the growth of patient volume. This efficient approach will allow cancer centers to share existing resources, give patients access to a collection of cancer-fighting therapies under one roof, and ensures new protons centers’ financial success in the expanding Chinese market.

Today, new proton therapy centers in the United States are almost exclusively compact single-room systems. As the first company to innovate this approach, Mevion has over 50% market share of compact single-room systems in the U.S. and has been the preferred compact room provider of NCI-Designated Cancer Centers. To date, over 5,000 patients have been treated on Mevion proton therapy systems.

For more information: www.mevion.com

Related Content

Conducted by the University of Gothenburg, Lund University and the University of South Australia, the preclinical study found that dietary oat bran can offset chronic gastrointestinal damage caused by radiotherapy, contradicting long-held clinical recommendations.

Getty Images

News | Radiation Therapy | October 07, 2020
October 7, 2020 — Loved or hated, the humble oat could be the new superfood for cancer patients as international ...
Microscopic photo of a professionally prepared slide demonstrating breast tissue with ductal carcinoma in situ (DCIS). Immuhistochemistry of estrogen receptor positive. Micrograph of breast cancer. Slide shows corresponding length of 1 mm.

Microscopic photo of a professionally prepared slide demonstrating breast tissue with ductal carcinoma in situ (DCIS). Immuhistochemistry of estrogen receptor positive. Micrograph of breast cancer. Slide shows corresponding length of 1 mm. Getty Images

News | Breast Imaging | October 05, 2020
October 5, 2020 — A major study of women with ductal carcinoma in situ (...
ASTRO urges radiation oncology benefits management company eviCore to reconsider a move that requires shorter treatment regimens without regard for physician judgement

Getty Images

News | Radiation Oncology | October 02, 2020
October 2, 2020 — Radiation oncologists expressed serious concerns about a new private insurance coverage policy that
Newly released study results present a strong case for lung cancer screening in New Zealand — particularly for Māori whose mortality rates are between three and four times higher than other ethnic groups.

Image courtesy of Siemens Healthineers

News | Lung Imaging | September 30, 2020
September 30, 2020 — Newly released study results present a strong case for...
he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...